Michelle Chico, MD
Endocrinology, Diabetes & Metabolism · Shreveport, LANPI 1053504662
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,775 of the $12,374 with a category attached, or 87.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,065, 2.5 times the $1,231 reported in 2019.
Across 524 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Dexcom, Inc.$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$821
- Cequr Corporation$631
- plus $4K from 21 others
What the payments were for
- Consulting fees$1131%
- Speaking & faculty fees$4504%
- Travel & lodging$1,0038%
- Food & beverage$10,77587%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $2,948 |
| Dexcom, Inc. | 53 | $1,660 |
| Lilly USA, LLC | 70 | $1,208 |
| Novo Nordisk | 77 | $1,055 |
| AstraZeneca | 38 | $821 |
| Cequr Corporation | 2 | $631 |
| Amarin Pharma, Inc. | 25 | $521 |
| Sanofi-aventis U.S. LLC | 30 | $476 |
| Bayer | 21 | $413 |
| Boehringer Ingelheim | 25 | $398 |
| Esperion Therapeutics, Inc. | 19 | $317 |
| Corcept Therapeutics | 18 | $315 |
| Amgen(2 entities) | 11 | $275 |
| Merck | 15 | $232 |
| Abbott | 11 | $179 |
| GRT US Holding, Inc. | 9 | $178 |
| AbbVie | 8 | $140 |
| Novartis | 7 | $126 |
| Xeris Pharmaceuticals, Inc. | 7 | $112 |
| Insulet Corporation | 6 | $108 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| ERBE USA Inc | 1 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Averitas Pharma Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,720
- CeQur Simplicity$631
- DEXCOM G6 TRANSMITTER$386
- FARXIGA$247
- Vascepa$125
- Repatha$125
- Kerendia$125
- JARDIANCE$121
How this compares
$12,374 in reported general payments places this provider in the 70th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 401 | $444,463 |
| JardianceEmpagliflozin | 465 | $439,731 |
| OzempicSemaglutide | 371 | $413,833 |
| TrulicityDulaglutide | 312 | $376,971 |
| Tresiba Flextouch U-200Insulin Degludec | 224 | $362,393 |
| Tresiba Flextouch U-100Insulin Degludec | 261 | $223,983 |
| FarxigaDapagliflozin Propanediol | 210 | $213,305 |
| KerendiaFinerenone | 184 | $202,494 |
| JanuviaSitagliptin Phosphate | 164 | $164,067 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 111 | $142,101 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 157 | $115,164 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $75,558 |
| VascepaIcosapent Ethyl | 107 | $69,190 |
| Repatha SureclickEvolocumab | 70 | $53,081 |
| Novolog FlexpenInsulin Aspart | 150 | $52,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,208 | $821,433713 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Synjardy Xr, Glyxambi | $398 | $672,976755 claims |
| Novo NordiskOzempic, Novolog | $1,055 | $420,662398 claims |
| AstraZenecaFarxiga | $821 | $213,305210 claims |
| BayerKerendia | $413 | $202,494184 claims |
| MerckJanuvia, Janumet | $232 | $182,783180 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $476 | $17,34018 claims |
| AbbVieSynthroid | $140 | $14,002163 claims |
| Esperion Therapeutics, Inc.Nexletol | $317 | $7,61117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Shreveport
- Dakota BostonShreveport$4K
- Binod PokhrelShreveport$3K
- Sirisha Reddy ThambuluruShreveport$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.